See What's Inside
Read this FREE issue now
For healthcare professionals only

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

A Product For When You Have Low Blood Sugar

Bill Abajian

A Product For When You Have Low Blood Sugar

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Victoza

Updated 7 weeks ago
Weekly Dulaglutide Performs Well in Comparison to Daily Liraglutide
Aug 1, 2014 | 
A comparison of the effects on A1c between users of once-weekly dulaglutide (made by Eli Lilly and Company) and once-daily liraglutide (sold as Victoza from Novo Nordisk) shows that both drugs have very similar effects.
NBA Hall of Famer Dominique Wilkins: Has A Slam Dunk Formula for Diabetes
Jun 30, 2014 | 
NBA Hall of Famer Dominique Wilkins, affectionately known as “The Human Highlight Film” has a few coaching tips for people with diabetes.
DHTV
Popular
Top Rated

Related Medications Videos on Diabetes Health TV

ReliOn at Wal-Mart

Bob Guest

ReliOn at Wal-Mart

A Product For When You Have Low Blood Sugar

Bill Abajian

A Product For When You Have Low Blood Sugar

Nipro Diabetes Systems Introduces The Amigo®

Tony Delamaza

Nipro Diabetes Systems Introduces The Amigo®

Weekly Type 2 Drug to Be Delivered Via Needle Patch
Feb 24, 2014 | 
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
First-World Type 2 Drug Market to Reach $47 Billion by 2022
Oct 18, 2013 | 
A Massachusetts-based research firm concludes that the first-world market for type 2 drugs and treatments will increase from $27 billion in sales in 2012 to $47 billion in 2022.
Lilly Says Its New Injectible Outperforms Three Popular Diabetes Drugs
Nov 20, 2012 | 
Good news for Eli Lilly & Co., as well as for type 2s who appreciate the addition of new drugs to treat their condition: Lilly says its once-weekly injectible drug, dulaglutide, has outperformed three other widely taken diabetes drugs in three just-concluded Phase III studies.
Paula Deen: Cooking Up a New Life With Diabetes
Aug 28, 2012 | 
Paula Deen, a celebrity Southern chef known for her unrestrained love of butter and sugar, is no stranger to the media. She received a flurry of bad press recently when she revealed that she had been diagnosed with type 2 diabetes three years earlier. Shortly thereafter, she became a spokesperson for Novo Nordisk's Victoza. Following these developments, some critics said that she was a poor role model. 
Am I Doing the Right Thing?
Mar 29, 2012 | 
Readers occasionally ask us for advice about drugs they are taking. When they do, we refer their questions to a medical professional. In the question below, a Florida reader expresses concerns about the interaction of her diabetes drug with the medicines she takes for asthma.
Next Page »  
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.